Nick Urban is an associate in the Antitrust
practice group at Berger & Montague. He concentrates his
practice in the area of complex antitrust litigation.
Mr. Urban focuses on antitrust class
actions alleging that pharmaceutical manufacturers wrongfully kept
less expensive generic drugs off the market, in violation of the
antitrust laws. These cases include In re Modafinil Antitrust
Litigation, 2:06-cv-01797 (E.D. Pa.) ($512 million settlement with
three of five defendants); In re Skelaxin (Metaxalone) Antitrust
Litigation, 1:12-md-02343 (E.D. Tenn.) ($73 million settlement); In
re Wellbutrin XL Antitrust Litigation, 2:08-cv-02431 (E.D. Pa.)
($37.5 million settlement with one of two defendants); In re Nexium
(Esomeprazole) Antitrust Litigation, 1:12-md-02409 (D. Mass.); In
re Niaspan Antitrust Litigation, 2:13-md-02460 (E.D. Pa.); In re
Aggrenox Antitrust Litigation, 3:13-cv-01776 (D. Conn.); In re
AndroGel Antitrust Litigation, 3:13-cv-01776 (N.D. Ga.).
He has also devoted significant time to
antitrust cases brought against the banking industry.
E.g., Ross and Wachsmuth v. American Express Co., et al.,
04-CV-5723 (S.D.N.Y.) ($49.5 million settlement); Ross, et al. v.
Bank of America, N.A. (USA), et al., 05-CV-7116 (S.D.N.Y.)
(obtained settlements with four of the nations' largest card
issuers (Bank of America, Capital One, Chase and HSBC) to drop
their arbitration clauses for their credit cards for 3.5
While at the University of Pennsylvania Law
School, Mr. Urban served as senior editor for the Journal of Law
and Social Change and worked at several organizations dedicated to
increasing the availability of quality affordable housing through
impact litigation and development. Prior to attending law
school, he worked as an anti-hunger advocate in the San Diego
region and for the Office of the Secretary of State of